CC
C4 Therapeutics, Inc.
CCCC · NASDAQ
$3.76 +1.08% (+$0.04)
1M +3.30%
Market Cap $413.5M
P/E Ratio -
Div. Yield -
ROE 45.45%
Piotroski F-Score Weak
3/9Valuation
48 /100
Fair P/B 1.67x
P/S 11.80x
EV/FFO N/A
Growth
36 /100
Stable Book val. growth 3.91%
Rev. growth 4.95%
FCF growth N/A
Profitability
20 /100
Weak Op. margin 318.97%
Gross margin 94.86%
FCF margin 243.71%
Quality
1 /100
Poor ROA 28.22%
ROIC 35.21%
Asset turnover 0.10x
Debt
100 /100
Low Current ratio 5.45x
Debt/Equity 0.23x
Debt/Assets N/A
Stability
25 /100
Unstable EPS volatility 22.62%
Beta 2.95x
Profitable years 0
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na CCCC
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Andrew J. Hirsch
Employees
104
Headquarters
Watertown
Nadcházející události
05 LIS
Earnings
Upcoming earnings report